EMA imposes formal limit on Xeljanz prescription as regulators continue to review safety...

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, May 18, 2019 at 9:12 PM.

  1. #1 cafead, May 18, 2019 at 9:12 PM
    cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    33,046
    Likes Received:
    3
    via Three months after Pfizer flagged blood clot issues and a higher rate of deaths for rheumatoid arthritis patients taking the 10 mg dose of Xeljanz (tofacitinib) in a post-marketing safety study, the EMA has handed down official restrictions in its use.

    article source
     
    Quote

Reply to Thread